Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
BrainAurora Medical Technology HK$583 million IPO
We advised BrainAurora on its IPO and HKEX listing
Teoxane proposal to acquire Revance Therapeutics
We are advising Teoxane on the proposed acquisition
Olema Pharmaceuticals $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Precigen $79 million preferred stock and warrants offering
We advised Precigen on the private placement
Personalis $50 million at-the-market offering
The shares are listed on the Nasdaq Global Market
Revolution Medicines $750 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Laekna HK$236 million placement of shares
We advised Laekna on the placement of new shares
Alignment Healthcare $330 million convertible senior notes offering
The convertible notes are due 2029
ACELYRIN $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market